Colorado Rocky Mountain Health Plans vision policy update | OpenPayer
ModifiedColorado Rocky Mountain Health PlansPolicy CS131.P
Visual Information Processing Evaluation and Orthoptic and Vision Therapy
Policy governing coverage and medical necessity of visual information processing evaluations, orthoptic therapy (vision therapy), occlusion and pharmacologic penalization, and prism adaptation for members of Colorado Rocky Mountain Health Plans; specifies covered indications and those considered unproven or not medically necessary.
Policy Summary
PayerColorado Rocky Mountain Health Plans
PolicyVisual Information Processing Evaluation and Orthoptic and Vision Therapy
Key ActionObtain prior authorization and submit documentation of prior conventional therapy, baseline BCVA and stereoacuity, and objective adherence data when requesting coverage for device-based or novel vision therapies.
Policy assigned identifier CS131.P with effective date February 1, 2026.
Specifies proven and medically necessary services (occlusion/pharmacologic penalization for amblyopia; orthoptic/vision therapy for convergence insufficiency; prism adaptation therapy for esotropia).
Lists therapies considered unproven and not medically necessary (orthoptic/vision therapy for other indications, virtual perception therapy for learning disabilities, vision restoration therapy post-stroke, visual information processing evaluation to diagnose learning disabilities, remote/online/digital therapy for amblyopia).
Removed content/language pertaining to the state of Louisiana.
Updated Clinical Evidence and References sections to reflect the most current information.
3proven indications
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
5+
unproven/not medically necessary (examples)
5CPT/temporary codes listed
2023-2025key study years cited
221CITT participants
~75%CITT children improved
Coverage Criteria and Evidence-Based Positions
inv-01: Proven and Medically Necessary Indications
Covered when ALL of the following are met for the listed proven indications
Amblyopia - Occlusion/Pharmacologic Penalization: Occlusion therapy (patching) or pharmacologic penalization (e.g., atropine) is considered proven and medically necessary for treating amblyopia.
See Cochrane review and PEDIG trial evidence supporting occlusion and atropine effectiveness.
Convergence Insufficiency - Orthoptic/Vision Therapy: Orthoptic therapy (office-based vision therapy with home reinforcement) is considered proven and medically necessary for treating symptomatic convergence insufficiency.
Supported by randomized trials demonstrating improvement in accommodative and vergence measures and symptoms.
Esotropia - Prism Adaptation Therapy: Prism adaptation therapy (PAT/PA) is considered proven and medically necessary for preoperative assessment and to inform surgical dosing in acquired esotropia.
RACT and PAS trial evidence show PAT can reveal dose-relevant angle changes and improve surgical success rates.
inv-02: Unproven / Not Medically Necessary Services
Not covered (unproven) when ANY of the following indications are the sole reason for therapy
Other indications for Orthoptic/Vision Therapy: Orthoptic therapy or vision therapy for indications other than amblyopia (when treated with occlusion/atropine), convergence insufficiency, or esotropia is unproven and not medically necessary.
Virtual perception therapy for learning/language disorders: Virtual perception therapy or behavioral/visual perceptual therapy to treat learning disabilities or language disorders is unproven and not medically necessary.
Vision Restoration Therapy for post-stroke deficits: Vision restoration therapy (VRT) for visual field deficits after stroke or neurotrauma is unproven and not medically necessary based on limited/low-quality evidence.
Visual information processing evaluation to diagnose learning disabilities: Visual information processing evaluation (VIPE) to diagnose reading or other learning disabilities is unproven and not medically necessary.
inv-03: Initial coverage criteria (proposed)
Possible covered when ALL of the following are met
Age and diagnosis: Patient falls within the age and diagnostic ranges evaluated in relevant trials (examples include children approximately 3–17 years depending on study/device) and has a confirmed diagnosis of amblyopia or symptomatic convergence insufficiency.match device/trial age ranges
Device indications and trial eligibility vary by product—match to device labeling and trial populations.
Prior standard therapy: For amblyopia, documentation of prior conventional therapy (full-time refractive correction and prescribed occlusion or pharmacologic penalization) is provided; for residual amblyopia prior patching regimen and response are documented (e.g., 2 hours/day prior to escalation).document prior patching regimen and adherence
PEDIG RCT evidence supports escalating patching from 2 to 6 hours for residual amblyopia before alternative treatments.
Objective baseline and outcome measures:
inv-04: Coverage when evidence-based parameters met
Coverage may be considered when clinical evidence and patient factors align with trial populations showing benefit.
Typical eligibility logic: Patient has amblyopia or symptomatic binocular/vergence disorder with documented baseline BCVA and stereoacuity; age consistent with studied populations; prior or concurrent conventional therapies (glasses, occlusion/atropine) documented when required; proposed treatment regimen (dose and duration) aligns with regimens evaluated in RCTs; objective adherence monitoring is available.age and duration per trial
Derived from phase 3 and pivotal RCTs where regimen, age, and baseline characteristics determined outcome relevance.
inv-05: Prism Adaptation Testing and Surgical Planning
PAT is indicated as a preoperative assessment to determine surgical dosing for acquired esotropia or decompensated esophoria/microesotropia.
PAT considerations: Individuals considered for strabismus surgery for acquired esotropia or decompensated esophoria/microesotropia should undergo prism adaptation testing (PAT) to reveal prism-adapted angle changes that inform augmented surgical dosing.angle change thresholds used in studies (e.g., ≥3 PD for decEPH; ≥10 PD observed in some decMET cases)
PAS and observational studies show PAT frequently increases measured angle and PAS RCT demonstrated improved surgical success when PA responders underwent augmented surgery.
inv-06: Evidence-supported therapies
Covered when ALL of the following are met (evidence-supported scenarios):
Prism Adaptation — preoperative augmentation: Patient is age ≥3 years with acquired horizontal deviation (e.g., 12–40 PD) and no prior eye muscle surgery; occlusion/amblyopia therapy completed if required; demonstrates prism response with motor stability and sensory fusion and is selected per trial criteria for augmented surgery.age >= 3; deviation 12-40 PD
PAS RCT randomized eligible participants and found higher surgical success in PA responders who underwent augmented surgery (89% vs 72%) and overall benefit of the PA process (83% vs 72%).
OBVAT for symptomatic CI or accommodative dysfunction: Patient (child or adolescent) has symptomatic convergence insufficiency and/or accommodative dysfunction documented by clinical measures (e.g., NPC, PFV, accommodative amplitude or facility); therapy is delivered as office-based vergence/accommodative therapy per RCT protocols with home reinforcement and documented objective improvement in targeted measures.documented symptomatic CI and abnormal accommodative measures
RCTs (Chen et al., Scheiman et al., Shin et al.) demonstrated significant improvements in amplitude, facility, NPC, PFV and symptom scores with OBVAT versus placebo or no treatment.
Not clearly covered / Experimental or insufficient evidence when ANY of the following apply:
Vision therapy for convergence excess or nystagmus: No well-designed clinical trials identified to support vision therapy for convergence excess or nystagmus; considered investigational or not medically necessary.N/A
Policy notes absence of RCT evidence for these indications.
Vision therapy for divergence excess or insufficiency: No well-designed clinical trials identified to support vision therapy for divergence excess or divergence insufficiency; considered investigational or not medically necessary.N/A
Lack of trial evidence for divergence disorders.
Orthoptic/VT for exotropia/esotropia — limited evidence: Evidence for orthoptic or vision therapy as primary treatment for exotropia or esotropia is limited, heterogeneous, and often short-term; routine coverage as a substitute for established surgical or conservative pathways is not supported without stronger evidence.
inv-08: Coverage summary and evidence-based positions
Summary stance based on available evidence across indications:
General coverage stance: Most orthoptic/vision therapy and vision restoration interventions have limited, low-quality, or conflicting evidence; routine coverage is not supported without condition-specific high-quality evidence and measurable clinical benefit.
Derived from systematic reviews and guideline summaries noting limited or mixed evidence.
Situations with some supportive evidence: Some interventions (office-based VT for convergence insufficiency; prism adaptation preoperative process; select digital binocular therapies in specified age/subtype groups) have RCT evidence of benefit when patient selection, dosing, and adherence match trial populations.
Examples include CITT/OBVAT trials, PAS, and CureSight/Xiao et al. trials showing benefit in defined populations.
Strabismus management summary: For intermittent distance exotropia and many strabismus presentations, conservative non-surgical treatments may have limited impact on angle or control scores compared with surgery; standard surgical and conventional therapies remain primary where indicated.
inv-09: Coverage-relevant evidence summary
Summarized coverage-relevant conclusions from clinical evidence and professional guidelines in the excerpt:
Evidence for VRT/NES/tDCS: Available RCTs, pilots, and case series for vision restoration approaches and non-invasive electrical stimulation show mixed results with heterogeneity and limited sample sizes; small or immediate gains in some perceptual or visual-field measures have been reported but clinical relevance and durability remain uncertain.
Systematic reviews and small RCTs highlight low-to-moderate certainty evidence and need for larger controlled trials.
Guideline positions on VT: Professional guidelines (AOA, NICE, VA/DoD, USPSTF) generally endorse conventional treatments for amblyopia and recommend orthoptist assessment and selective use of therapies; AOA supports VT for several binocular and accommodative disorders but notes limited evidence for home-based VT alone.
Guidelines emphasize refractive correction and occlusion as primary amblyopia treatments and recommend office-based VT with home reinforcement for certain binocular disorders.
inv-10: Guideline and device-based indications and evidence
Clinical guidance and evidence statements cited that support vision therapy for certain conditions and note limitations:
AOA-supported indications: AOA guidance states vision therapy can be effective for ocular motility dysfunctions, non-strabismic binocular disorders, strabismus, amblyopia, and accommodative disorders, and may be used in visual sequelae of acquired brain injury, while noting prognostic advantages for intermittent or recent-onset strabismus.
AOA guidelines recommend office-based VT combined with home therapy and describe VT goals and target deficits.
Office-based plus home therapy preference: AOA and guideline statements favor office-based vision therapy combined with home reinforcement rather than home-based therapy alone because therapist oversight improves technique, motivation, and outcomes.
AOA guideline notes limited data supporting home-based VT as sole therapy.
Amblyopia primary treatments: USPSTF and other guidance recommend primary amblyopia treatment with refractive correction and occlusion/pharmacologic penalization; vision therapy is described as an adjunctive active remediation but conventional treatments remain mainstays.
For clarity of coverage operations, Orthoptic/Vision Therapy (VT) does not include refractive treatment or refractive lenses; VT refers to supervised in‑office programs with home reinforcement aimed at improving binocular function and oculomotor control (e.g., vergence, accommodation, fixation) rather than provision of corrective spectacles or refractive services.
Behavioral or visual perceptual therapies used as psychoeducational interventions to address learning, speech, or language delays are outside the scope of orthoptic/VT as defined here and are considered separate, non‑ophthalmologic services; documentation should therefore distinguish orthoptic procedures from any visual information processing evaluations or educationally focused interventions.
Remote, online, and other digital amblyopia therapies have limited and heterogeneous clinical evidence; many studies are single‑arm, have short follow‑up, or show high dropout rates, and so remote/digital VT may be excluded when proposed as a sole replacement for established conventional treatments.
Randomized trials and reviews report mixed findings: some dichoptic or game‑based programs show within‑group improvements, but comparative RCTs often do not demonstrate superiority to patching and adherence can be substantially lower in older adolescents — these limitations support requiring robust comparative evidence, adequate follow‑up, and adherence data when remote/digital VT is requested.
When coverage is sought for a home or digital device, prior documentation should show prior conventional therapy attempts (e.g., refractive correction and prescribed patching) and trial‑relevant objective baseline and adherence data consistent with the device’s evaluated population.
Meta‑analyses and systematic reviews of binocular/digital therapies for amblyopia report substantial heterogeneity across trials and inconsistent between‑group effects; several reviews conclude binocular approaches cannot universally replace conventional patching and that observed VA gains may be sensitive to participant age, total hours of intervention, and short study duration.
Because of high heterogeneity, short follow‑up, and variable adherence in many included trials, evidence does not support indiscriminate substitution of binocular/digital therapies for patching across all patient groups; coverage determinations should consider trial populations, duration, and adherence outcomes.
Where noninferiority trials exist for specific devices and age ranges, coverage decisions should be limited to those device indications and require documentation matching the populations and dosing used in the supporting studies.
For several vergence and ocular motor disorders (for example, convergence excess, divergence excess, and nystagmus), the policy review identified no well‑designed randomized clinical trials supporting VT as effective; absence of high‑quality trial evidence limits routine coverage for these indications.
In the absence of rigorous trial data, requests for therapy to treat these specific vergence or ocular motor disorders should be considered investigational and require clear, condition‑specific justification and objective baseline measurements if submitted for prior authorization.
Routine use of a range of restitutive, compensatory, and experimental interventions — including prism adaptation for post‑stroke neglect, vision restoration therapy (VRT), non‑invasive electrical stimulation (NES), and many visual perceptual learning programs — is not supported as standard therapy due to limited, inconsistent, or low‑quality evidence of meaningful functional benefit.
These approaches often suffer from small sample sizes, heterogeneity of methods, short follow‑up, and conflicting results; therefore routine authorization without strong, study‑specific justification is not recommended.
When such therapies are proposed, prior authorization should require submission of the clinical rationale, prior conservative treatments tried, objective baseline outcome measures, and a plan for measurable follow‑up outcomes.
Behavioral or perceptual vision therapies, including programs like perceptual learning software, are supported only by limited and often low‑quality evidence; current reviews note conflicting findings and weak study designs that limit confidence in clinical benefit.
Adjunctive or alternative modalities promoted to address learning disabilities or academic performance are not endorsed by major pediatric and ophthalmologic organizations and should not be used as a substitute for evidence‑based ophthalmic care.
Behavioral/perceptual vision therapies, training glasses, prisms, colored filters, and similar adjunctive devices are not recommended for diagnosing or treating learning disabilities; authoritative joint statements conclude there is inadequate evidence that such interventions improve educational outcomes.
Where these approaches are proposed for visual efficiency or learning‑related claims, the request should be denied absent high‑quality evidence demonstrating clinically meaningful benefit for the stated educational or developmental outcome.
The VA/DoD 2022 clinical practice guideline states there is insufficient evidence to recommend for or against any particular modality for treating visual symptoms attributed to mild traumatic brain injury (e.g., diplopia, accommodation/convergence deficits, visual tracking deficits, photophobia).
Consequently, routine coverage of VT for mild TBI–related visual symptoms should be considered investigational unless higher‑quality evidence emerges to support a specific modality.
Policy language referencing state‑specific provisions has been updated; references and templates previously containing content specific to Louisiana have been removed from this version.
Operationally, coverage decisions must follow applicable state and contractual requirements; this policy no longer contains Louisiana‑specific text and should be applied per the member’s jurisdictional plan terms.
Examples of explicit denials include orthoptic/vision therapy when the sole indication is not one of the proven conditions (amblyopia treated with conventional methods, convergence insufficiency, or prism adaptation for esotropia).
Virtual perception therapy or behavioral/perceptual VT requested for learning disabilities, language disorders, or educational performance claims are considered unproven and not medically necessary and should be denied when submitted as the primary indication.
Concerns about the quality of evidence for digital and remote VT — including single‑arm designs, short follow‑up, heterogeneity of devices, and high attrition in some trials — may form the basis for exclusion or denial when these modalities are proposed without strong comparative RCT evidence.
Providers seeking coverage for remote/digital therapies should submit randomized comparative evidence, long‑term outcomes, and adherence data aligning with the treated patient’s age and amblyopia type to mitigate exclusion risk.
Trials that show no advantage of a novel therapy over standard care, or that demonstrate poor adherence (for example, low completion rates in device‑prescribed dosing), inform operational denials — offering such therapies in lieu of proven treatments may be considered not medically necessary.
When trial data indicate adherence is a critical determinant of effectiveness, plans may require objective adherence monitoring or prior success with standard treatments before approving alternative or digital VT.
Current evidence does not support vision therapy as effective treatment for convergence excess, divergence excess/insufficiency, or as a standard therapy after stroke or traumatic brain injury; available studies are limited, conflicting, or lacking rigorous design.
Requests for VT for these indications should be considered investigational or not medically necessary in routine practice unless robust, indication‑specific evidence is provided.
Prism adaptation for unilateral post‑stroke neglect has not demonstrated consistent short‑ or long‑term benefit compared with sham or standard care in pooled analyses; meta‑analytic results do not support routine PA therapy for unilateral post‑stroke neglect.
Therefore routine authorization of prism adaptation for post‑stroke neglect should not be approved without compelling, patient‑specific evidence that aligns with trial protocols showing benefit.
Vision therapy as a procedural approach is not regulated as a procedure by the FDA; however, specific devices used in VT programs vary in regulatory status — some have FDA clearances or De Novo decisions while others may be exempt or unregulated.
Device regulatory status does not by itself determine coverage; when a digital therapeutic has device labeling or prescription requirements (e.g., age ranges or supervised use), those constraints should guide appropriate patient selection and documentation.
Applicable Codes and Regulatory References
Applicable CPT/Temporary Codesmixed
0687T
Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session.
0688T
Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month.
0704T
Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment.
0705T
Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days.
0706T
Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month.
92065
Orthoptic training; performed by a physician or other qualified health care professional.
92066
Orthoptic training; under supervision of a physician or other qualified health care professional.
92499
Unlisted ophthalmological service or procedure.
Device regulatory references (no billing codes listed)mixed
No codes listed
CITT success criteria for convergence — clinical thresholds for NPC and PFV
Near point of convergence (NPC)Normal NPC defined as < 6 cm; success may also be defined as improvement ≥ 4 cm from baseline.
Positive fusional vergence (PFV)Normal PFV defined as passing Sheard's criterion with base-out break > 15Δ.
PFV improvement thresholdAn alternative success criterion is an increase in base-out break ≥ 10Δ compared with baseline.
Prior Authorization, Documentation, and Operational Guidance
Prior Authorization
Prior Authorization for Listed Codes
Prior authorization may be required for services billed with the CPT/temporary codes listed in this policy. Coverage is limited to medically necessary indications and is subject to the member's contract, federal and state requirements.
Prior authorization applicable when billing any listed codes
Prior authorization requirements vary by plan/contract
Documentation Required
Prior Authorization: Clinical Baseline and Trial Details
Prior authorization requests for vision therapy, digital/binocular home treatments, or other novel vision interventions should include detailed baseline and trial-specific clinical information: indication, prior conventional therapies attempted, objective baseline measures, adherence to prior therapy, and the planned follow-up and outcome measures.
Indication and rationale for therapy
Clinical Background and Definitions
Amblyopia is decreased vision in one or both eyes due to abnormal visual development in infancy or childhood; conventional, evidence‑based treatments include refractive correction, occlusion (patching), and pharmacologic penalization (atropine) to encourage use of the amblyopic eye.
Orthoptic/Vision Therapy describes structured, supervised in‑office sessions with at‑home reinforcement exercises aimed at improving binocular function, vergence, and accommodation; these programs are adjunctive to, and do not replace, evidence‑based primary amblyopia treatments unless supported by high‑quality comparative evidence.
Amblyopia — definition and concise description
DefinitionDecreased vision in one or both eyes due to abnormal visual development in infancy and childhood; the brain does not properly learn to interpret images from the affected eye (often called 'lazy eye').
Usual onsetDevelops in early childhood when visual pathways fail to be properly stimulated.
Primary treatments referencedRefractive correction, occlusion (patching), and pharmacologic penalization (atropine) are mainstays of therapy per guidelines.
Policy Revision History and Updates
2026-04-01template_updateLatest
Template update removed Louisiana-specific language from the policy.
2026-02-01policy_effective_date
Policy assigned identifier CS131.P with effective date February 1, 2026; supporting information and references were updated and previous version CS131.O archived.
Policy Summary
PayerColorado Rocky Mountain Health Plans
PolicyVisual Information Processing Evaluation and Orthoptic and Vision Therapy
Key ActionObtain prior authorization and submit documentation of prior conventional therapy, baseline BCVA and stereoacuity, and objective adherence data when requesting coverage for device-based or novel vision therapies.
Remote/online/digital therapy for amblyopia: Remote, online, and/or digital therapy for amblyopia (when proposed as a sole replacement for established standard treatments) is considered unproven and not medically necessary pending stronger comparative and long-term evidence.
Baseline and planned outcome measures are documented: best-corrected visual acuity (BCVA) in amblyopic eye, stereoacuity, and other trial-relevant metrics with planned follow-up intervals to demonstrate change.
use trial-consistent measures (e.g., logMAR lines)
Objective measures are necessary to assess benefit and medical necessity.
Device-specific evidence: When requesting coverage for a specific binocular/home device (e.g., CureSight, Luminopia One), provide trial evidence demonstrating efficacy and safety in the patient’s age and amblyopia subtype and adherence data supporting use in that population.evidence matches device labeling and studied populations
CureSight pivotal RCT (ages 4 to <9) showed noninferiority to patching and higher adherence in mostly anisometropic amblyopia.
N/A
RCTs and cohort data show mixed short-term benefits for control or stereopsis but inconsistent long-term angle improvement; surgery often yields greater angle/control benefits.
Post-stroke and traumatic brain injury: Orthoptic/vision therapy and restitutive/compensatory/substitutive interventions for post-stroke visual field defects and TBI have limited, low-quality, or conflicting evidence and are considered investigational or case-by-case.N/A
Systematic reviews report insufficient high-quality evidence to support routine use.
Cohort and RCT evidence indicate surgery often yields larger improvements in angle/control for many patients.
Guidelines emphasize refractive correction and patching/atropine as first-line.
Post-stroke visual rehabilitation guidance: NICE recommends specialist orthoptist assessment and offers eye movement therapy for persisting hemianopia after stroke; VA/DoD finds insufficient evidence to support any particular modality for mild TBI visual symptoms.
Guidelines provide selective recommendations and note limited evidence for many modalities.
Device-specific indications: Some digital therapeutics (e.g., CureSight, Luminopia One, RevitalVision) have FDA clearances or De Novo classification for amblyopia in defined age ranges and are intended for prescription use per labeling; device labeling constrains use to trained professionals and specified regimens.
FDA decisions cited include CureSight clearance and Luminopia One De Novo classification with age and usage constraints.
History of prior conventional therapy (hours/duration of patching, pharmacologic penalization, refractive correction)
Objective baseline measures (BCVA, angle of deviation, stereoacuity, control scores, visual field metrics where applicable)
Adherence data for prior treatments
Proposed therapy plan, duration, and follow-up schedule
Prior Authorization
Prior Authorization Recommended for Select Indications
Prior authorization is recommended for specific indications where evidence supports benefit (for example, prism adaptation for esotropia and office-based vergence/accommodative therapy with home reinforcement for symptomatic convergence insufficiency). Provide trial eligibility and supporting evidence when requesting coverage for these indications.
Prism adaptation therapy for acquired esotropia (document motor stability and sensory fusion responses)
Office-based vergence/accommodative therapy with home reinforcement for convergence insufficiency (document diagnostic criteria and change in convergence measures)
Prior Authorization
Prior Authorization Recommended for Experimental / Limited-Evidence VT/VRT
Interventions with limited, contradictory, or evolving evidence (for example, vision restoration therapy, non-invasive electrical stimulation, tDCS, many digital perceptual learning programs, and some VRT/NES approaches) should be prior authorized when billed so plans can review clinical necessity and current evidence.
Non-invasive electrical stimulation (NES), transcranial direct current stimulation (tDCS)
Vision Restoration Therapy (VRT) and many digital perceptual learning programs (RevitalVision, NovaVision)
Novel or device-based home/binocular therapies without robust long-term sham-controlled RCT data
Prior Authorization
Prior Authorization May Be Required Per Plan
Plans may require prior authorization based on contract terms. Verify specific prior authorization rules with the member's plan or contract; absence of prior authorization in this policy does not guarantee coverage without plan approval.
Prior authorization requirements depend on federal/state/contractual terms
Check member's benefit plan for prior authorization portals and submission requirements
Denial Risk
Evidence Limitations May Trigger Denial or Non-Coverage
Evidence limitations — including small sample sizes, single-arm designs, short follow-up, high dropout rates, heterogeneous populations, and lack of sham-controlled trials — may be grounds for denial or non-coverage of a requested therapy.
High dropout rates or single-arm designs in supporting studies
Insufficient long-term durability data for chronic conditions (e.g., amblyopia, post-stroke visual field loss)
Heterogeneity of device types and protocols limiting generalizability
Denial Risk
Evidence-Related Denial Risk for Limited / Conflicting Therapies
When evidence is limited or conflicting for a requested indication (for example, many uses of VRT, NES, visual perceptual therapy, or digital VT for non-approved indications), plans may determine the service not medically necessary and deny coverage.
Lack of consistent RCT data or long-term outcomes
Conflicting systematic review conclusions or low-certainty evidence
Documentation Required
Required Documentation Elements
Provide complete documentation to support medical necessity. Required elements include the diagnosis, targeted functional deficits, therapy goals, prior treatment history, objective baseline measures, and measurable outcome expectations.
Diagnosis and clinical rationale
Therapy goals and measurable outcomes
Prior treatment history (refractive correction, hours of prior patching, prior surgeries)
Documentation Required
Required Clinical Documentation and Measures
Required clinical documentation should include: best-corrected visual acuity (BCVA) for each eye, angle of deviation (prism diopters), near stereoacuity, control scores for exotropia, and objective visual field or perimetry measures when applicable.
BCVA (pre- and post-treatment)
Angle of deviation measured by PACT or cover test (near and distance)
Near stereoacuity and binocular visual acuity
Control scores (e.g., NCS) and visual field/perimetry results where relevant
Documentation Required
Example Trial Eligibility and Documentation Expectations
Example trial eligibility and documentation expectations: document age limits, prior surgery status, acuity thresholds, prior conventional therapy duration/adherence, baseline objective measures, and intended treatment dosing and monitoring.
Age and inclusion/exclusion criteria used to justify therapy (e.g., 4–9 years for certain device trials)
Prior conventional therapy attempted and duration (e.g., minimum weeks of patching)
Baseline and scheduled follow-up VA, stereoacuity, and adherence monitoring data
Documentation Required
Suggested Clinical Documentation
Suggested clinical documentation for novel interventions may include pre- and post-treatment measures such as detection accuracy, mean sensitivity on perimetry, reaction time, and validated quality-of-life or activities-of-daily-living (ADL) measures when relevant to the indication.
High-resolution perimetry detection accuracy and mean sensitivity
Validated QoL or ADL functional measures for post-stroke interventions
Objective adherence logs for home-based therapies
Documentation Required
Device Regulatory and Prescribing Context
Device regulatory and prescribing context: note FDA clearances and intended use when relevant. Some digital therapeutics (e.g., Luminopia One, CureSight) are FDA-cleared or de‑novo authorized and intended for prescription use per manufacturer labeling; include device indication, age range, and prescription status in requests.
Include device name, FDA decision or 510(k)/De Novo identifier, indicated age range, and prescription requirements
Indicate whether device was used per labeled instructions and supervised by a trained eye-care professional
Note
Reference to Contractual, Federal, and State Requirements
Coverage decisions must be made in the context of federal, state, and contractual benefit terms. In case of conflict between this policy and plan/federal/state requirements, the applicable contractual or statutory requirement governs.
Verify and cite applicable federal/state mandates or plan contract language when making coverage determinations
UnitedHealthcare/plan-specific tools (e.g., InterQual) may be used to support decisions
Step Therapy
Preferred and Stepwise Therapy Pathways; Conservative-First Approach
Preferred therapy pathways and conservative-first approaches: document attempts with conventional, guideline-recommended therapies prior to authorizing alternative or adjunctive vision training interventions. Examples include escalating patching before alternative therapies and prioritizing conventional treatments for amblyopia and strabismus.
Preferred pathway for convergence insufficiency: office-based vergence/accommodative therapy with home reinforcement preferred over home-only approaches
Stepwise escalation of occlusion for amblyopia (increase from 2 to 6 hours/day for residual amblyopia before alternative therapies)
Consider conventional therapy (refractive correction, patching, pharmacologic penalization) before digital VT
Stepwise non-surgical management for intermittent exotropia; consider conservative measures before surgery except when evidence or acuity indicates surgical benefit
Conventional treatments remain first-line; VT/VRT considered adjunctive or targeted in select cases
Note
None Stated
Orthoptic Therapy — definition
DefinitionA structured series of in-office eye exercises (orthoptics/vision therapy) performed weekly over months, often with at-home reinforcement, intended to improve binocular function and eye movement control.
ProvidersPerformed by orthoptists or other trained eye-care professionals within ophthalmology/optometry practices.
ComponentsMay include evaluation and measurement of deviations, targeted exercises, and home practice to manage amblyopia and small intermittent symptomatic deviations.
Prism Adaptation Therapy — definition
DefinitionUse of prisms to bend light to permit alignment of the visual axes, simulate absence of strabismus, and help determine the angle of deviation or surgical target angle.
Clinical roleUsed diagnostically (Prism Adaptation Test) and therapeutically to reveal prism-adapted angles that may inform augmented surgical dosing for esotropia.
Evidence contextRandomized and observational studies (e.g., PAS RCT) demonstrated prism adaptation can increase surgical success when used to guide augmented surgery.
Vision Restoration Therapy (VRT) — definition
DefinitionIn-home, computer-based repetitive training programs intended to stimulate residual visual processing areas to improve detection sensitivity and visual field function after neurological injury or disease.
Typical deliveryDelivered via computer programs or software for home use; examples include behavioral activation of residual vision and border-stimulation paradigms.
EvidenceSystematic reviews and small RCTs/pilot studies report limited, heterogeneous evidence with uncertain clinical relevance; larger, confirmatory trials are needed.
Office-based vision therapy (VT) — definition and CITT reference
DefinitionStructured in-office orthoptic/vision therapy sessions supervised by a clinician, combined with prescribed home exercises, aimed at improving vergence, accommodation, and binocular function.
CITT referenceOffice-based VT with home reinforcement was the most effective arm in the CITT RCT (nearly 75% of children achieved normal vision or fewer CI symptoms after 12 weeks).
Typical courseProtocols commonly span 12–16 weeks with weekly office visits plus daily home practice as used in randomized trials.
DefinitionUse of pharmacologic drops (e.g., atropine) in the sound eye to blur vision and encourage use of the amblyopic eye (pharmacologic penalization).
Comparative efficacyCochrane review evidence indicates atropine penalization is as effective as conventional occlusion (patching) in improving visual acuity in amblyopia, with different adverse event profiles and sometimes better adherence.
Adverse eventsAtropine associated with light sensitivity and occasional reduced VA in the good eye; patching associated with skin/lid irritation.
Binocular/dichoptic therapy (e.g., CureSight) — definition and context
DefinitionHome-based binocular/dichoptic treatments present complementary or contrast-rebalanced stimuli to each eye (games, movies, or eye-tracking displays) to reduce suppression and promote binocular vision and stereopsis in amblyopia.
Clinical contextPivotal RCTs (e.g., CureSight) compared binocular home treatment to patching and demonstrated noninferior VA improvements and higher adherence in select pediatric populations (ages 4 to <9 years).
LimitationsMost trials enrolled primarily anisometropic amblyopia and have variable generalizability to strabismic or mixed-mechanism amblyopia; long-term durability and subgroup effects remain incompletely characterized.
DefinitionTherapies that deliver different images to each eye (often with contrast adjustments) to reduce suppression of the amblyopic eye and encourage binocular combination, delivered via games, movies, or VR devices.
MechanismContrast-rebalancing or dichoptic presentation aims to rebalance input and permit simultaneous binocular use, potentially improving VA and stereopsis.
Evidence summarySystematic reviews and RCTs show mixed results; some trials demonstrate VA and stereopsis gains and improved adherence for home binocular approaches versus patching in selected groups.
Prism Adaptation Test (PAT) — definition
DefinitionA diagnostic procedure using prisms to reveal the maximum or 'true' angle of ocular deviation prior to strabismus surgery to optimize surgical dosing.
Use in planningPAT can uncover increased angles of deviation under prism adaptation that inform whether augmented surgical dosing is appropriate.
Observed effectsRetrospective and RCT data show PAT can increase measured angle (examples: mean increases of several pdpt), and a substantial proportion of patients demonstrate clinically relevant angle changes during PAT.
Prism Adaptation (PA/PAT) — definition and trial context
DefinitionPrism adaptation (PA/PAT) entails applying prisms to adapt the measured ocular deviation before deciding on surgical dosing; in trials, prism responders were randomized to augmented versus conventional surgery based on prism-adapted angles.
Trial contextThe multicenter PAS RCT randomized participants (age ≥3, deviations 12–40 PD) and found higher surgical success when the PA process guided augmented surgery (overall PA process success 83% vs 72%).
Selection criteria in trialsTypical trial entry included 20/40 or better VA in each eye and prior occlusion for amblyopic individuals; responders to prisms showing motor stability and sensory fusion were candidates for augmented dosing in studies.
Office-Based Vergence/Accommodative Therapy (OBVAT) — definition and trial context
DefinitionOffice-Based Vergence/Accommodative Therapy (OBVAT) is supervised in-office vision therapy specifically targeting vergence and accommodative systems, typically delivered with structured weekly sessions plus home practice.
Trial evidenceRandomized trials (e.g., CITT, Scheiman et al., 2011; Chen et al., 2021) demonstrate OBVAT improves NPC, PFV, accommodative amplitude, and facility compared with placebo or no treatment in symptomatic children and adolescents.
Outcome measuresTrials measured NPC, PFV, CISS symptom scores, accommodative amplitude and facility, with protocols commonly spanning 12–16 weeks and showing durable improvements in many participants on follow-up.
Visual Field Defect (VFD) — definition
DefinitionVisual field defect (VFD) refers to loss or impairment of portions of the visual field (e.g., homonymous hemianopia) often assessed with standard perimetry such as Humphrey visual field testing.
CausesCommonly results from stroke, traumatic brain injury, or other neurological lesions affecting visual pathways.
Rehabilitation contextInterventions for VFDs include restitutive (VRT), compensatory (scanning training), and substitutive (prism) approaches, but high-quality evidence of functional benefit is limited.
DefinitionPerceptual learning (PL) or visual perceptual therapy uses repeated practice on targeted visual tasks (e.g., orientation, discrimination, motion) delivered via software or VR to improve visual function.
Delivery modesOften delivered as computer-based training programs or VR modules; examples include RevitalVision and other perceptual-learning platforms.
EvidenceSystematic reviews report mixed and limited-quality evidence; some trials show objective vision measure improvements but clinical relevance and generalizability are uncertain.
Prism Adaptation (PA) — definition for post-stroke neglect context
DefinitionPrism Adaptation (PA) in the post-stroke neglect context uses prism goggles to shift the visual field laterally to retrain spatial attention, tested against sham or no treatment in trials for unilateral spatial neglect.
EvidenceSystematic reviews found inconsistent effects and limited-quality evidence for routine use in post-stroke unilateral neglect; some studies report short-term improvements in scanning ability but not consistent ADL benefit.
Adverse effectsPrism use may cause minor adverse effects such as headache; clinical impact on functional outcomes remains uncertain.
DefinitionNon-invasive electrical stimulation (NES) includes transcutaneous or transcranial electrical stimulation techniques applied to attempt improvement in visual function (often studied with VRT or as adjuncts).
Evidence summarySystematic reviews of RCTs report small, short-term improvements in visual acuity, detection accuracy, or quality of life with low-to-moderate certainty; minor adverse effects are more likely than with sham.
Research statusHeterogeneous study designs and small sample sizes limit conclusions; further well-designed RCTs are recommended.
DefinitionComputer-based repetitive training targeting visual field borders and residual vision (behavioral activation) to improve detection sensitivity and visual field function; usually home- or clinic-based software programs.
ModalitiesMay be delivered alone or combined with neuromodulation (e.g., tDCS) in pilot studies and small trials.
EvidenceRandomized and controlled small trials report detection accuracy gains in some settings (e.g., glaucoma, post-stroke) but require confirmation in larger, longer-term studies.
Vision Therapy (VT) / Orthoptics — definition
DefinitionVision therapy (VT)/orthoptics encompasses active, supervised training procedures (in-office and often with home practice) designed to improve oculomotor control, vergence, accommodation, fusion, and related sensory-motor function for conditions such as amblyopia, strabismus, and vergence/accommodative dysfunction.
Typical componentsExercises, lenses (training glasses), prisms, filters, patches, electronic targets, and therapist guidance delivered over weeks to months.
Guideline contextAOA and specialty guidelines describe VT as effective for selected disorders (ocular motility dysfunctions, non-strabismic binocular disorders, accommodative disorders) but note limitations for home-only programs.
Expanded definitionVT/orthoptics aims to improve fixation, oculomotor control, reduce amblyopia, enhance sensory and motor fusion, and increase accommodative and vergence facility and range through supervised training.
Delivery and supervisionPreferred clinical management often involves office-based therapy combined with home reinforcement because home-only programs lack therapist oversight and may be less effective.
Indications referencedAOA identifies multiple indications where VT may be effective including strabismus, amblyopia, accommodative/vergence dysfunctions, and visual sequelae of brain injury—while evidence strength varies by condition.
Visual efficiency vs visual information processing — definition and distinction
Visual efficiencyPhysiological processes including visual acuity, accommodation, vergence, and ocular motility.
Visual information processingHigher-level brain functions of perception and cognition integrating vision with motor, auditory, language, and attention systems.
DistinctionVisual efficiency problems are physiologic deficits potentially addressed by refractive correction and VT; visual information processing deficits involve cognitive integration and may require more complex interventions, with evidence and guideline positions differing between domains.
Amblyopia and vision therapy evidence — references cited in definitions/background
Key evidence types citedRandomized clinical trials, systematic reviews/meta-analyses, and professional guidelines (AOA, AAO, USPSTF) are referenced across amblyopia, convergence insufficiency, prism adaptation, VRT, NES, and perceptual learning literature.
Amblyopia evidenceCochrane review and multiple RCTs show atropine penalization and patching improve VA; binocular/dichoptic device trials (e.g., CureSight) show noninferiority in select pediatric populations but generalizability is limited.
Convergence insufficiency evidenceCITT and related RCTs demonstrate office-based VT improves clinical measures (NPC, PFV) and symptoms in children, supporting OBVAT as evidence-based for symptomatic CI.